Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

1.9K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
1.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

3.8K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

504
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

JAMA dermatology·2026
Same author

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.

Investigational new drugs·2026
Same author

Genomic Predictors of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Insights from an MD Anderson Cohort.

Journal of the American Academy of Dermatology·2026
Same author

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Neoadjuvant PD-1 Blockade in Surgically Resectable Desmoplastic Melanoma: Cohort A of the Phase 2 SWOG S1512 Trial.

Annals of surgical oncology·2026
Same author

Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Jun 20, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.4K

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.

Susan M Swetter1, Douglas Johnson2, Mark R Albertini3

  • 1Stanford Cancer Institute.

Journal of the National Comprehensive Cancer Network : JNCCN
|July 17, 2024
PubMed
Summary
This summary is machine-generated.

The NCCN Guidelines for Cutaneous Melanoma Version 2.2024 update recommendations for neoadjuvant systemic therapy. New clinical data on melanoma treatment options were evaluated by the NCCN panel.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Related Experiment Videos

Last Updated: Jun 20, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.4K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Area of Science:

  • Oncology
  • Dermatology
  • Clinical Guidelines

Background:

  • The National Comprehensive Cancer Network (NCCN) provides guidelines for cutaneous melanoma diagnosis and treatment.
  • Updates are crucial for incorporating the latest clinical evidence into patient care.

Purpose of the Study:

  • To summarize updates in neoadjuvant systemic therapy for cutaneous melanoma.
  • To highlight new clinical data evaluated for the NCCN Guidelines Version 2.2024.

Main Methods:

  • Review of recent clinical data by the NCCN panel.
  • Inclusion of updated recommendations in the NCCN Guidelines for Cutaneous Melanoma.

Main Results:

  • The NCCN Guidelines Version 2.2024 include updated neoadjuvant systemic therapy options.
  • New clinical data have been evaluated and incorporated into treatment recommendations.

Conclusions:

  • The updated NCCN Guidelines offer current evidence-based recommendations for cutaneous melanoma management.
  • Neoadjuvant systemic therapy options are a key focus of the latest guideline revisions.